A groundbreaking study conducted by biomedical engineers at Duke University has unveiled a revolutionary method for oral delivery of GLP-1 peptide drugs, circumventing the need for fasting and preserving the medication’s therapeutic efficacy. This innovative approach could herald a paradigm shift in administering peptide-based pharmaceuticals, which traditionally rely on injections due to the digestive system’s destructive breakdown of peptides. The research, published on May 13, 2026, in the prestigious journal Cell Biomaterials, holds transformative potential not only for weight loss medications like GLP-1 analogs Ozempic and Wegovy but also for a wide spectrum of peptide therapies including insulin, treatments for irritable bowel syndrome, HIV, and osteoporosis.
Peptides, short chains of amino acids that perform crucial biological functions across healing, hormone regulation, and muscle synthesis, pose a formidable delivery challenge due to their fragile nature in the gastrointestinal environment. Unlike small molecule drugs that withstand the acidic and enzymatic milieu of the stomach, peptides are rapidly degraded, severely limiting oral bioavailability. Consequently, patients are often required to endure daily injections, a significant barrier to widespread acceptance and adherence. Acknowledging this critical limitation, the Duke research team turned to the biological inspiration of elastin-like polypeptides (ELPs), naturally occurring sequences that exhibit unique physical properties conducive to drug delivery innovations.
The specially engineered ELPs exhibit intrinsically disordered protein characteristics that allow them to transition between liquid and solid states based on environmental triggers such as pH and temperature. This switchability directly addresses the challenge of protecting peptide drugs through the hostile stomach, ensuring their intact transit until reaching the more conducive environment of the intestines. Unlike existing oral GLP-1 formulations that require administration on an empty stomach and utilize bases to neutralize stomach acid, the ELP-based delivery system dissolves these constraints, maintaining drug potency without fasting prerequisites.
Drawing an evolutionary parallel, Max Ney, the study’s lead author and a postdoctoral researcher at ETH Zurich formerly at Duke, leveraged the protective mechanisms observed in yeast cells, where self-assembling polypeptides shield intracellular components under stress-induced acidity. Inspired by this natural phenomenon, the team synthesized a biomaterial that mimics this self-assembly, conjugating GLP-1 drugs with peptides programmed to form protective bioparticles responsive to gastrointestinal environmental cues. These bioparticles are stable solids that traverse the acidic stomach, disintegrating only upon encountering the specific pH and temperature conditions of the intestines, thus releasing the drug payload effectively.
The implications of this technology were tested in vivo using murine models fed high-calorie diets, where the orally delivered GLP-1 bioparticles demonstrated weight loss efficacy comparable to conventional injections. The scalability of this method is bolstered by the production feasibility via Escherichia coli, a well-established bacterial system widely used in pharmaceutical manufacturing, promising cost-effective and large-scale implementation. This contrasts favorably with current small molecule oral GLP-1 candidates in clinical trials, which reportedly suffer from diminished efficacy despite more convenient dosing schedules.
Further technical details reveal that the scientists meticulously designed synthetic ELP sequences by manipulating their amino acid compositions to fine-tune their responsiveness to temperature and acidity. This bespoke engineering ensures robust stability in the gastric environment while enabling rapid dissolution in the intestine. The plasticity of these polypeptides’ physical states implicates broader applications beyond GLP-1 analogs, potentially revolutionizing oral delivery protocols for numerous peptide drugs historically hindered by gastrointestinal degradation.
Senior researcher Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering, emphasized the decade-long commitment of his laboratory to customizing ELPs for a myriad of biomedical applications, underpinning the significance of this leap in oral peptide delivery technology. The research embodies an intricate fusion of biomaterials science, molecular biology, and pharmaceutical engineering, showcasing innovative translational potential from bench to bedside.
Addressing needle-phobia prevalence, which affects a sizeable portion of patients using peptide therapeutics, these oral delivery advancements promise improved patient compliance, quality of life, and broader accessibility. Importantly, the method sidesteps the gastric acid neutralization required by current oral peptide drugs, removing dietary restrictions and enabling flexibility in dosing times, which could significantly enhance treatment adherence.
The research received funding support from the Air Force Office of Scientific Research, emphasizing the strategic interest in advanced drug delivery systems. The team envisions expansive future studies encompassing diverse peptide drugs suffering from oral bioavailability limitations, potentially unlocking previously inaccessible therapeutic regimens.
In summary, the Duke University team’s intrinsically disordered protein coating strategy represents a monumental advance in oral peptide drug delivery, combining nature-inspired biomolecular engineering with clinical practicality. By overcoming longstanding gastrointestinal challenges, this innovation not only opens new pathways for the treatment of obesity and diabetes but also signals a broader revolution in the administration of peptide-based medicines.
Subject of Research: Animals
Article Title: Intrinsically disordered protein coating for oral delivery of peptide drugs
News Publication Date: 13-May-2026
Web References: 10.1016/j.celbio.2026.100460
References: Ney, M., Sirohi, P., Shmidov, Y., Singh, A., Wadsworth, G., Li, X., Zheng, J., Peng, E., Fan, L., Mahendran, T. S., Deshpande, S., Tripathi, N., Su, J. C., Milligan, J. J., Wang, Y.-X., Banerjee, P. R., & Chilkoti, A. (2026). Intrinsically disordered protein coating for oral delivery of peptide drugs. Cell Biomaterials. https://doi.org/10.1016/j.celbio.2026.100460
Keywords: Drug delivery systems, Pharmaceuticals, Biomedical engineering, Materials engineering, Body weight
Tags: biomedical engineering in peptide therapeuticsDuke University biomedical research on peptideselastin-like polypeptides for drug deliveryGLP-1 analogs Ozempic and Wegovyinjectable to oral peptide therapy transitioninnovative peptide pharmaceutical methodsnon-fasting GLP-1 medication administrationoral delivery of insulin and peptidesoral GLP-1 peptide drug deliveryovercoming peptide degradation in stomachpeptide drug oral bioavailabilitypeptide drug stability in gastrointestinal tract
